Skip to main content

NLRP1/NALP1 Antibody [DyLight 594]

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-76656DL594

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human

Applications

ELISA, Immunocytochemistry/ Immunofluorescence, Western Blot

Label

DyLight 594 (Excitation = 593 nm, Emission = 618 nm)

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Summary for NLRP1/NALP1 Antibody [DyLight 594]

Immunogen

Antibody was raised against a peptide corresponding to 13 amino acids near the carboxy terminus of human NALP1. The immunogen is located within the last 50 amino acids of NALP1. Amino Acid Squence: EKGSKKGLLPLSS

Reactivity Notes

0

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for NLRP1/NALP1 Antibody [DyLight 594]

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Immunocytochemistry/ Immunofluorescence

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Affinity purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: NLRP1/NALP1

NALP1 (also known as NAC/CARD7) is a member of the CATERPILLER (CLR) diverse multigene superfamily of immune regulatory proteins (Ting and Davis, 2005). CLR proteins have a variable N-terminal domain, followed by a nucleotide-binding domain (NBD) and leucine-rich repeats (LRR). The N-terminal domain consists of transactivation, CARD, Pyrin or BIR domains, or in some cases is undefined. The CLR family, also known as the NOD family, has its ancient roots in the plant kingdom and is related to the disease resistance (R) gene family that mediates plant immune responses. CLR proteins participate in both innate and adaptive immunity in mammals, some act as sensors that detect pathogen products, and several CLR genes have been linked to susceptibility to immunological diseases. It is thought that the CLR family may have a fundamental importance for the function of the mammalian innate/ancient immune system on par with the Toll-like receptor (TLR) family. NALP1, a member of NALP CLR subfamily, has an N-terminal pyrin domain (PYD), followed by an NBD, LRR, and a C-terminal CARD domain (reviewed in Tschopp. NALP1 is a component of both the inflammasome and apoptosome, suggesting that NALP1 it has important roles in both inflammation and apoptosis. This antibody recognizes NALP1; human NALP1 is a 1473 amino acid protein and migrates at approx. 166 kDa on SDS-PAGE. However, multiple splice variants encoding distinct NALP1 isoforms with varying amino acid lengths have been described and thus the molecular weight detected may vary depending on the isoform(s) expressed.

Long Name

NLR Family, Pyrin Domain Containing 1

Alternate Names

CARD7, CLR17.1, DEFCAP, NALP1, PP1044, SLEV1, VAMAS1

Gene Symbol

NLRP1

Additional NLRP1/NALP1 Products

Product Documents for NLRP1/NALP1 Antibody [DyLight 594]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for NLRP1/NALP1 Antibody [DyLight 594]



DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...